Insmed reported $137.65M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
DBV Technologies DBVT:US USD 28.39M 2.04M
Acelrx Pharmaceuticals ACRX:US USD 15.65M 2.04M
Alimera Sciences ALIM:US USD 34.01M 8.58M
Biomarin Pharmaceutical BMRN:US USD 521.02M 56.29M
Cytokinetics CYTK:US USD 76.5M 9.65M
Dynavax Technologies DVAX:US USD 244.08M 101.12M
Gilead Sciences GILD:US USD 10.42B 1.2B
Heron Therapeutics HRTX:US USD 93.88M 15.62M
Insmed INSM:US USD 137.65M 23.84M
Mirati Therapeutics MRTX:US USD 126.99M 7.84M
Novartis NVS:US USD 28.16B 514M
Ophthotech OPHT:US USD 24.59M 1.89M
Regeneron Pharmaceuticals REGN:US USD 2.88B 154.7M
Sarepta Therapeutics SRPT:US USD 602.92M 57.35M
Seattle Genetics SGEN:US USD 726M 117.48M
Ultragenyx Pharmaceutical RARE:US USD 227.36M 6.72M
Vertex Pharmaceuticals VRTX:US USD 2.61B 53.1M